Health Technology · Pharmaceuticals: Major · NSE: NEULANDLAB · data 2026-10-09

Neuland Laboratories Ltd.

Health check: Strong (7.9/10 on quality, valuation vs sector, growth and momentum).

Open full analysis — chart, results, balance sheet, red flags →

Key figures

Price

₹20,890

Market cap

₹26,961 cr

P/E

53.8

P/B

—

ROE

21.4%

ROCE

23.8%

Debt / equity

0.16

Dividend yield

0.16%

1-year return

34.6%

52-week high

₹24,225

52-week low

₹11,500

Operating margin

28.0%

Growth

Revenue (last 12 months)	₹2,372 cr
Net profit (last 12 months)	₹498 cr
Sales growth, 3 years (yearly)	19.3%
Profit growth, 3 years (yearly)	30.6%

Similar companies

Emcure Pharmaceuticals Limited (EMCURE) · Wockhardt Limited (WOCKPHARMA) · Piramal Pharma Limited (PPLPHARMA) · Acutaas Chemicals Ltd (ACUTAAS) · Shilpa Medicare Limited (SHILPAMED)

The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.

Open NEULANDLAB in NSE Scanner →